Correlation between jaundice and vitamin D and NADSYN1 gene polymorphism in full-term neonates

doi:10.11958/20211522

Abstract

Abstract:

Objective To study the relationship between full-term neonatal jaundice, vitamin D (VD) levels, and single nucleotide polymorphisms (SNP) at rs12785878 of NADSYN1 gene. Methods The clinical data of 216 full-term infants with neonatal jaundice were retrospectively analyzed. The serum VD level was detected by liquid chromatography tandem mass spectrometry (LC-MS/MS), and a high-resolution melting curve (HRM) method was established to analyze the SNP of the NADSYN1 gene rs12785878 site. The infants were divided into groups according to whether they were older than 14 days, and the risk factors of hyperbilirubinemia were analyzed respectively. Results In infants ≤14 days, infection, cesarean and breast feeding were risk factors for hyperbilirubinemia. In infants >14 days, infection and hypoplasma protein were risk factors for hyperbilirubinemia. The established HRM analysis method of the rs12785878 site had a normal amplification reaction, and the genotypes of GG, GT and TT were well distinguished. The proportion of GG genotype and G allele was higher in the case group than that in the control group. In infants ≤14 days, the average VD value was higher in the TT genotype than that of the GG genotype [(12.61±5.23) μg/L vs. (9.62±4.24) μg/L, P<0.05]. Conclusion The GG genotype at rs12785878 of NADSYN1 gene is a risk factor for hyperbilirubinemia and low VD level in neonates ≤14 days old, which can be used as a new reference for the diagnosis and treatment of hyperbilirubinemia in full-term neonates.

Key words: hyperbilirubinemia,neonatal, vitamin D, polymorphism,single nucleotide, infant,newborn, NAD, NADSYN1, rs12785878

CLC Number:

R722.17

Figures/Tables 7

References 29

[1]	ZAHED PASHA Y, ALIZADEH-TABARI S, ZAHED PASHA E, et al. Etiology and therapeutic management of neonatal jaundice in Iran:a systematic review and meta-analysis[J]. World J Pediatr, 2020, 16(5):480-493. doi: 10.1007/s12519-020-00339-3.
[2]	SHAPIRO S M, RIORDAN S M. Review of bilirubin neurotoxicity II:preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders[J]. Pediatr Res, 2020, 87(2):332-337. doi: 10.1038/s41390-019-0603-5.
[3]	MAILHOT G, WHITE J H. Vitamin D and immunity in infants and children[J]. Nutrients, 2020, 12(5):1233. doi: 10.3390/nu12051233.
[4]	SZOT J O, CAMPAGNOLO C, CAO Y, et al. Bi-allelic mutations in NADSYN1 cause multiple organ defects and expand the genotypic spectrum of congenital NAD deficiency disorders[J]. Am J Hum Genet, 2020, 106(1):129-136. doi: 10.1016/j.ajhg.2019. 12.006.
[5]	LIN J, ZHAO L, ZHAO S, et al. Disruptive NADSYN1 variants implicated in congenital vertebral malformations[J]. Genes (Basel), 2021, 12(10):1615. doi: 10.3390/genes12101615.
[6]	MOHAMMAD R H, POURHOSSEINGHOLI M A, YADEGAR A, et al. High-resolution melt curve analysis:A real-time based multipurpose approach for diagnosis and epidemiological investigations of parasitic infections[J]. Comp Immunol Microbiol Infect Dis, 2019, 67:101364. doi: 10.1016/j.cimid.2019.101364.
[7]	MUTLU M, CAYIR A, CAYIR Y, et al. Vitamin D and hyperbilirubinaemia in neonates[J]. Hong Kong J Paediatr, 2013, 18:77-81.
[8]	ALETAYEB S M, DEHDASHTIYAN M, AMINZADEH M, et al. Comparison between maternal and neonatal serum vitamin D levels in term jaundiced and nonjaundiced cases[J]. J Chin Med Assoc, 2016, 79(11):614-617. doi: 10.1016/j.jcma.2016.05.008.
[9]	MEHRPISHEH S, MEMARIAN A, MAHYAR A, et al. Correlation between serum vitamin D level and neonatal indirect hyperbilirubinemia[J]. BMC Pediatr, 2018, 18(1):178. doi: 10.1186/s12887-018-1140-9.
[10]	盛晓阳, 向伟, 王卫平, 等. 儿童微量营养素缺乏防治建议[J]. 中华儿科杂志, 2010, 48(7):502-509.
	SHENG X Y, XIANG W, WANG W P, et al. Recommendations for prevention and treatment of micronutrient deficiency in children[J]. Chin J Pediatr, 2010, 48(7):502-509. doi: 10.3760/cma.j.issn.0578-1310.2010.07.006.
[11]	WANG TJ, ZHANG F, RICHARDS J B, et al. Common genetic determinants of vitamin D insufficiency:a genome-wide association study[J]. Lancet, 2010, 376(9736):180-188. doi: 10.1016/S0140-6736(10)60588-0.
[12]	BERGMANN A U, THORKELSSON T. Incidence and risk factors for severe hyperbilirubinemia in term neonates[J]. Laeknabladid, 2020, 106(3):139-143. doi: 10.17992/lbl.2020.03.473.
[13]	赵惠琴, 张新华. 新生儿高胆红素血症的病因分析和临床特点探讨[J]. 中国基层医药, 2015, 22(3):380-382.
	ZHAO H Q, ZHANG X H. Analysis of etiology and clinical characteristics of neonatal hyperbilirubinemia[J]. Chinese Journal of Primary Medicine and Pharmacy, 2015, 22(3):380-382. doi: 10.3760/cma.j.issn.1008-6706.2015.03.020
[14]	EZEAKA C V, UGWU R O, MUKHTAR-YOLA M, et al. Pattern and predictors of maternal care-seeking practices for severe neonatal jaundice in Nigeria:A multi-centre survey[J]. BMC Health Serv Res, 2014, 4:192. doi: 10.1186/1472-6963-14-192.
[15]	LIU Y, SUN X, WANG Y, et al. Evaluation of associated markers of neonatal pathological jaundice due to bacterial infection[J]. Iran J Public Health, 2021, 50(2):333-340. doi: 10.18502/ijph.v50i2. 5394.
[16]	DEMIRARAN Y, ALBAYRAK M, SEKER I S, et al. Effect of anesthesiological strategies on neonatal bilirubin levels during cesarean section:a prospective and randomized trial[J]. Arch Gynecol Obstet, 2011, 284(5):1059-1065. doi: 10.1007/s00404-010-1783-8.
[17]	GOURLEY G R, LI Z, KREAMER B L, et al. A controlled,randomized,double-blind trial of prophylaxis against jaundice among breastfed newborns[J]. Pediatrics, 2005, 116(2):385-391. doi: 10.1542/peds.2004-1807.
[18]	CHIU Y W, CHENG S W, YANG C Y, et al. Breastfeeding in relation to neonatal jaundice in the first week after birth:parents' perceptions and clinical measurements[J]. Breastfeed Med, 2021, 16(4):292-299. doi: 10.1089/bfm.2020.0293.
[19]	HUDSON J A, CHARRON E, MAPLE B, et al. Baby-friendly hospital initiative is associated with lower rates of neonatal hyperbilirubinemia[J]. Breastfeed Med, 2020, 15(3):176-182. doi: 10.1089/bfm.2019.0220.
[20]	WANG H Q, KONG E L, ZHANG X, et al. Folic acid alleviates jaundice of phenylhydrazine(PHA)-induced neonatal rats by reducing Lys-homocysteinylation of albumin[J]. Cell Biol Toxicol, 2021, 37(5):679-693. doi: 10.1007/s10565-021-09602-3.
[21]	PÉREZ-LÓPEZ F R, PASUPULETI V, MEZONES-HOLGUIN E, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes:a systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2015, 103(5):1278-1288.e4. doi: 10.1016/j.fertnstert.2015.02.019.
[22]	MOON R J, DAVIES J H, COOPER C, et al. Vitamin D,and maternal and child health[J]. Calcif Tissue Int, 2020, 106(1):30-46. doi: 10.1007/s00223-019-00560-x.
[23]	JIANG X, O'REILLY P F, ASCHARD H, et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels[J]. Nat Commun, 2018, 9(1):260. doi: 10.1038/s41467-017-02662-2.
[24]	ALAYLİOĞLU M, DURSUND E, GENC G, et al. Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinson’s disease[J]. Int J Neurosci, 2022, 132(5):439-449. doi: 10.1080/00207454.2020.1820502.
[25]	LIBUDA L, NAARESH R, LUDWIG C, et al. A mendelian randomization study on causal effects of 25(OH)vitamin D levels on attention deficit/hyperactivity disorder[J]. Eur J Nutr, 2021, 60(5):2581-2591. doi: 10.1007/s00394-020-02439-2.
[26]	LIU H, JIANG X, QIAO Q, et al. Association of circulating 25-Hydroxyvitamin D and its related genetic variations with hepatocellular carcinoma incidence and survival[J]. Ann Transl Med, 2020, 8(17):1080. doi: 10.21037/atm-20-1637.
[27]	LIU X, WU P, SHEN L, et al. DHCR7 rs12785878 T>C polymorphism is associated with an increased risk of early onset of Alzheimer's disease in Chinese population[J]. Front Genet, 2021, 12:583695. doi: 10.3389/fgene.2021.583695.
[28]	DENNERY P A, WENG Y H, STEVENSON D K, 等. 血红素加氧酶:一种血红素代谢酶及其近况[J]. 中国当代儿科杂志, 2001, 3(4):350-351,366.
	DENNERY P A, WENG Y H, STEVENSON D K, et al. Heme oxygenase:a heme cababolic enzyme and more[J]. Chin J Contemp Pediatr, 2001, 3(4):350-351,366.
[29]	IRIE J, INAGAKI E, FUJITA M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men[J]. Endocr J, 2020, 67(2):153-160. doi: 10.1507/endocrj.EJ19-0313.

组别	n		男婴				日龄（d）			出生体质量（g）				妊娠天数（d）
对照组1	60		37（61.7）				4（1,12）			3 372±408				278（268,283）
高胆组1	44		23（52.3）				7（5,10）			3 351±412				274（270,280）
χ²、Z或t			0.918				1.824			0.251				1.456
组别	胎次：G1P1				剖宫产				血pH				血清VD（μg/L）
对照组1	31（51.7）				31（51.7）				7.40（7.35,7.46）				12.1±5.6
高胆组1	17（38.6）				33（75.0）				7.40（7.38,7.46）				10.9±3.7
χ²、Z或t	1.734				5.839^＊				0.862				1.232
组别		TBIL （μmol/L）				孕母年龄（岁）					孕母受教育程度（大专及以上）				母乳喂养
对照组1		160.4±32.8				29.4±4.4					37（61.7）				31（51.7）
高胆组1		280.0±55.2				28.7±4.1					31（70.5）				36（81.8）
χ²、Z或t		12.814^＊＊				0.813					0.866				10.096^＊＊
组别	感染			血糖（mmol/L）				血浆蛋白（g/L）				白蛋白（g/L）
对照组1	6（10.0）			4.82±0.87				54.0（51.1,57.0）				38.2（35.8,40.1）
高胆组1	15（34.1）			5.15±1.22				51.9（49.9,54.9）				38.7（36.9,41.1）
χ²、Z或t	9.142^＊＊			1.604				2.201^＊				1.033

组别	n		男婴				日龄（d）			出生体质量（g）				妊娠天数（d）
对照组1	60		37（61.7）				4（1,12）			3 372±408				278（268,283）
高胆组1	44		23（52.3）				7（5,10）			3 351±412				274（270,280）
χ²、Z或t			0.918				1.824			0.251				1.456
组别	胎次：G1P1				剖宫产				血pH				血清VD（μg/L）
对照组1	31（51.7）				31（51.7）				7.40（7.35,7.46）				12.1±5.6
高胆组1	17（38.6）				33（75.0）				7.40（7.38,7.46）				10.9±3.7
χ²、Z或t	1.734				5.839^＊				0.862				1.232
组别		TBIL （μmol/L）				孕母年龄（岁）					孕母受教育程度（大专及以上）				母乳喂养
对照组1		160.4±32.8				29.4±4.4					37（61.7）				31（51.7）
高胆组1		280.0±55.2				28.7±4.1					31（70.5）				36（81.8）
χ²、Z或t		12.814^＊＊				0.813					0.866				10.096^＊＊
组别	感染			血糖（mmol/L）				血浆蛋白（g/L）				白蛋白（g/L）
对照组1	6（10.0）			4.82±0.87				54.0（51.1,57.0）				38.2（35.8,40.1）
高胆组1	15（34.1）			5.15±1.22				51.9（49.9,54.9）				38.7（36.9,41.1）
χ²、Z或t	9.142^＊＊			1.604				2.201^＊				1.033

因素	B	SE	Wald χ²	P	OR	OR 95%CI
剖宫产	1.018	0.492	4.285	0.038	2.766	1.056~7.250
母乳喂养	1.483	0.538	7.604	0.006	4.405	1.536~12.639
感染	1.906	0.641	8.848	0.003	6.727	1.916~23.622
血浆蛋白	-0.080	0.057	2.013	0.156	0.923	0.826~1.031
血清VD	-0.032	0.050	0.398	0.528	0.969	0.878~1.069
常数项	2.318	3.094	0.561	0.454	10.154

因素	B	SE	Wald χ²	P	OR	OR 95%CI
剖宫产	1.018	0.492	4.285	0.038	2.766	1.056~7.250
母乳喂养	1.483	0.538	7.604	0.006	4.405	1.536~12.639
感染	1.906	0.641	8.848	0.003	6.727	1.916~23.622
血浆蛋白	-0.080	0.057	2.013	0.156	0.923	0.826~1.031
血清VD	-0.032	0.050	0.398	0.528	0.969	0.878~1.069
常数项	2.318	3.094	0.561	0.454	10.154

组别				n	男婴				日龄（d）					出生体质量（g）
对照组2				60	28（46.7）				25.0（18.0,29.8）					3 332±368
高胆组2				52	29（55.8）				23.5（20.3,29.0）					3 226±430
χ²、Z或t					0.924				0.368					1.410
组别		妊娠天数（d）					胎次：G1P1			剖宫产			母乳喂养				感染
对照组2		278（272,281）					21（35.0）			26（43.3）			52（86.7）				6（10.0）
高胆组2		271（268,277）					18（34.6）			24（46.2）			48（92.3）				16（30.8）
χ²、Z或t		2.759^＊					0.002			0.090			0.927				7.613^＊
组别			血糖（mmol/L）					血浆蛋白（g/L）			白蛋白（g/L）					血pH
对照组2			5.03（4.58,5.41）					55.4±3.9			39.9（37.8,41.0）					7.42±0.07
高胆组2			4.81（4.19,5.47）					52.0±3.1			39.1（37.7,41.2）					7.42±0.08
χ²、Z或t			0.321					5.034^＊＊			0.426					0.124
组别	血清VD （μg/L）					TBIL （μmol/L）						母亲年龄（岁）			母亲受教育程度（大专及以上）
对照组2	19.71±9.04					23.2（19.2,27.9）						29.1±4.4			33（55.0）
高胆组2	16.36±7.04					162.4（133.6,227.7）						30.5±4.0			31（59.6）
χ²、Z或t	2.202^＊					8.420^＊＊						1.710			0.242